Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7322)	1/23/2004 10:03:02 AM
From: rkrw	Read Replies (1) \| Respond to of 10280

It's not impressive to me if sepr matches industry standards yet has an ice strategy. Agree on oxy, I think similar to soltara, the opp came and went. Oxy I long thought (and have posted here years past) could have been outlicensed to jnj as a successor to their long acting oxybutynin product. If formulation truly is the bottleneck maybe jnj's alza could have tried. It's very difficult to rate sepr pipeline beyond estorra and MDI. They've changed their tune on norvasc, sounds like no change in edema but they figured out after a few years that even with ankle edema norvasc sells $b's and maybe they can use it as a base to a combo. This I think is a good idea.